Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272571 | 0.77 | — | — | |
| SCHEMBL17589058 | 0.77 | RAB9A (0.40) | RAB9ANPC1SMN1; SMN2PARP15PARP10 | |
| SCHEMBL14162629 | 0.74 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2PARP15PARP10 | |
| SCHEMBL272570 | 0.74 | — | — | |
| SCHEMBL15241323 | 0.72 | — | — | |
| SCHEMBL3052817 | 0.72 | — | — | |
| SCHEMBL5962368 | 0.72 | — | — | |
| SCHEMBL14451325 | 0.72 | — | — | |
| SCHEMBL13327032 | 0.72 | RAB9A (0.41) | RAB9ANPC1SMN1; SMN2PARP15PARP10 | |
| SCHEMBL24924285 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081748-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-11529343-B2 | Compositions and methods for identifying and treating dystonia disorders | DUKE UNIVERSITY (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3433243-B1 | NOVEL DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2 | INST NAT SANTE RECH MED (FR) | 2021-09-08 | — | — | EP | disclosed |
| US-20210069175-A1 | Compositions and Methods for Identifying and Treating Dystonia Disorders | DUKE UNIVERSITY (US) | 2021-03-11 | — | — | US | disclosed |
| US-20190100508-A1 | NOVEL DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2 | UNIVERSITÉ PARIS CITÉ (FR) | 2019-04-04 | — | — | US | disclosed |
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-9795608-B2 | Protein kinase inhibitors | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-9447102-B2 | Protein kinase inhibitors | PHARMASCIENCE, INC. (CA) | 2016-09-20 | — | — | US | disclosed |
| US-20150344478-A1 | PROTEIN KINASE INHIBITORS | GB005, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2015-07-09 | — | — | US | disclosed |
| US-7741345-B2 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7723380-B2 | Tetrahydrofuro[2,3-b]furyl carbamates containing an (oxy)hydrazide group; these compounds target the HIV protease in both wild type and mutant strains of HIV. | GILEAD SCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723380-B2 | Tetrahydrofuro[2,3-b]furyl carbamates containing an (oxy)hydrazide group; these compounds target the HIV protease in both wild type and mutant strains of HIV. | GILEAD SCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090105279-A1 | Antiviral protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105279-A1 | Antiviral protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099096-A1 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105279-A1 | Antiviral protease inhibitors | ACE, TMPRSS15, MME | RAB9A 1820/4885NPC1 406/4885SMN1; SMN2 2343/4885 |
| US-11529343-B2 | Compositions and methods for identifying and treating dystonia disorders | DDHD2, SMN1; SMN2, MYO3B | RAB9A 1832/4885NPC1 3741/4885SMN1; SMN2 2/4885 |
| US-20150344478-A1 | PROTEIN KINASE INHIBITORS | TEC, BTK, LCK | RAB9A 2258/4885NPC1 3512/4885SMN1; SMN2 4455/4885 |
| US-20190100508-A1 | NOVEL DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2 | CASP2, CASP1, CASP5 | RAB9A 4045/4885NPC1 2970/4885SMN1; SMN2 3481/4885 |
| US-20070299263-A1 | Hydroxy Alkyl Amines | MAOA, PSEN2, PSEN1 | RAB9A 1576/4885NPC1 161/4885SMN1; SMN2 492/4885 |
| US-20210069175-A1 | Compositions and Methods for Identifying and Treating Dystonia Disorders | DDHD2, SMN1; SMN2, MYO3B | RAB9A 1832/4885NPC1 3741/4885SMN1; SMN2 2/4885 |
| US-20090099096-A1 | AZA-peptide protease inhibitors | DNPEP, ANPEP, PEPD | RAB9A 1497/4885NPC1 1414/4885SMN1; SMN2 2815/4885 |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | ACE, DNPEP, TMPRSS15 | RAB9A 1786/4885NPC1 375/4885SMN1; SMN2 2337/4885 |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | TEC, SRC, LCK | RAB9A 2243/4885NPC1 4039/4885SMN1; SMN2 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.